Search alternatives:
significant base » significant based (Expand Search), significant cause (Expand Search), significant bias (Expand Search)
degs decrease » mean decrease (Expand Search), we decrease (Expand Search), deaths decreased (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
base case » use case (Expand Search)
significant base » significant based (Expand Search), significant cause (Expand Search), significant bias (Expand Search)
degs decrease » mean decrease (Expand Search), we decrease (Expand Search), deaths decreased (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
base case » use case (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Base-case analysis.
Published 2025“…At a CET of 0.51 times GDP per capita (US$6,394.536), the base-case analysis showed that the incremental costs of AOM relative to PP1M after 10 years of treatment were US$1,926.373 with an incremental gain of 0.306 QALYs. …”
-
10
-
11
-
12
-
13
-
14
-
15
-
16
Transepithelial electrical resistance (TEER) (N = 6).
Published 2024“…<p><b>(A)</b> During the cultivation of SMC and ALI we observed significantly differences on day 18 (SMC: 9.61 kΩ*cm<sup>2</sup>; ALI: 7.73 kΩ*cm<sup>2</sup>; p<0.05) and day 25 (SMC: 8.19 kΩ*cm<sup>2</sup>; ALI: 6.44 kΩ*cm<sup>2</sup>; p<0.05) ALI cultures showed significantly decreased values compared to SMC. …”
-
17
-
18
-
19
-
20
The base case analysis.
Published 2025“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”